Top

Published in:

01-04-2006 | Review

Most recent developments in strategies to reduce the progression of structural changes in osteoarthritis: today and tomorrow

Authors: Jean-Pierre Pelletier, Johanne Martel-Pelletier, Jean-Pierre Raynauld

Published in: Arthritis Research & Therapy | Issue 2/2006

Abstract

Osteoarthritis (OA), the most common of all arthritic conditions, is a social and financial burden to all nations. The most recent research has significantly advanced our understanding of the cause of OA and risk factors associated with it. These findings have provided useful information that has helped in the daily management of patients with OA. Some preventative measures and a number of therapeutic agents and drugs are available, which may help to reduce the progression of OA in certain patients. Moreover, the most recent progress in research has significantly enhanced our knowledge of the factors involved in the development of the disease and of the mechanisms responsible for its progression. This has allowed identification of several new therapeutic targets in a number of pathophysiological pathways. Consequently, the field is opening up to a new era in which drugs and agents that can specifically block important mechanisms responsible for the structural changes that occur in OA can be brought into development and eventually into clinical trials.

Felson DT, Goggins J, Niu J, Zhang Y, Hunter DJ: The effect of body weight on progression of knee osteoarthritis is dependent on alignment. Arthritis Rheum. 2004, 50: 3904-3909. 10.1002/art.20726.PubMed

Sharma L, Lou C, Felson DT, Dunlop DD, Kirwan-Mellis G, Hayes KW, Weinrach D, Buchanan TS: Laxity in healthy and osteoarthritic knees. Arthritis Rheum. 1999, 42: 861-870. 10.1002/1529-0131(199905)42:5<861::AID-ANR4>3.0.CO;2-N.PubMed

Sharma L, Song J, Felson DT, Cahue S, Shamiyeh E, Dunlop DD: The role of knee alignment in disease progression and functional decline in knee osteoarthritis. JAMA. 2001, 286: 188-195. 10.1001/jama.286.2.188.PubMed

Lajeunesse D, Pelletier JP, Martel-Pelletier J: Osteoarthritis: a metabolic disease induced by local abnormal leptin activity?. Curr Rheumatol Rep. 2005, 7: 79-81.PubMed

Lajeunesse D, Delalandre A, Fernandes J: Subchondral osteoblasts from osteoarthritic patients show abnormal expression and production of leptin: possible role in cartilage degradation [Abstract]. J Bone Miner Res. 2004, 19: S149-

Dumond H, Presle N, Terlain B, Mainard D, Loeuille D, Netter P, Pottie P: Evidence for a key role of leptin in osteoarthritis. Arthritis Rheum. 2003, 48: 3118-3129. 10.1002/art.11303.PubMed

Miller GD, Nicklas BJ, Davis CC, Ambrosius WT, Loeser RF, Messier SP: Is serum leptin related to physical function and is it modifiable through weight loss and exercise in older adults with knee osteoarthritis?. Int J Obes Relat Metab Disord. 2004, 28: 1383-1390. 10.1038/sj.ijo.0802737.PubMed

Ettinger WH, Burns R, Messier SP, Applegate W, Rejeski WJ, Morgan T, Shumaker S, Berry MJ, O'Toole M, Monu J, et al: A randomized trial comparing aerobic exercise and resistance exercise with a health education program in older adults with knee osteoarthritis. The Fitness Arthritis and Seniors Trial (FAST). JAMA. 1997, 277: 25-31. 10.1001/jama.277.1.25.PubMed

van Baar ME, Assendelft WJ, Dekker J, Oostendorp RA, Bijlsma JW: Effectiveness of exercise therapy in patients with osteoarthritis of the hip or knee: a systematic review of randomized clinical trials. Arthritis Rheum. 1999, 42: 1361-1369. 10.1002/1529-0131(199907)42:7<1361::AID-ANR9>3.0.CO;2-9.PubMed

10.

Baker KR, Nelson ME, Felson DT, Layne JE, Sarno R, Roubenoff R: The efficacy of home based progressive strength training in older adults with knee osteoarthritis: a randomized controlled trial. J Rheumatol. 2001, 28: 1655-1665.PubMed

11.

Lane NE, Michel B, Bjorkengren A, Oehlert J, Shi H, Bloch DA, Fries JF: The risk of osteoarthritis with running and aging: a 5-year longitudinal study. J Rheumatol. 1993, 20: 461-468.PubMed

12.

Lane NE, Oehlert JW, Bloch DA, Fries JF: The relationship of running to osteoarthritis of the knee and hip and bone mineral density of the lumbar spine: a 9 year longitudinal study. J Rheumatol. 1998, 25: 334-341.PubMed

13.

Roos EM, Dahlberg L: Positive effects of moderate exercise on glycosaminoglycan content in knee cartilage: a four-month, randomized, controlled trial in patients at risk of osteoarthritis. Arthritis Rheum. 2005, 52: 3507-3514. 10.1002/art.21415.PubMed

14.

Wilder FV, Hall BJ, Barrett JP, Lemrow NB: History of acute knee injury and osteoarthritis of the knee: a prospective epidemiological assessment. The Clearwater Osteoarthritis Study. Osteoarthritis Cartilage. 2002, 10: 611-616. 10.1053/joca.2002.0795.PubMed

15.

Lohmander LS, Ostenberg A, Englund M, Roos H: High prevalence of knee osteoarthritis, pain, and functional limitations in female soccer players twelve years after anterior cruciate ligament injury. Arthritis Rheum. 2004, 50: 3145-3152. 10.1002/art.20589.PubMed

16.

Hill CL, Seo GS, Gale D, Totterman S, Gale ME, Felson DT: Cruciate ligament integrity in osteoarthritis of the knee. Arthritis Rheum. 2005, 52: 794-799. 10.1002/art.20943.PubMed

17.

Hellio Le Graverand MP, Vignon E, Otterness IG, Hart DA: Early changes in lapine menisci during osteoarthritis development: Part I: cellular and matrix alterations. Osteoarthritis Cartilage. 2001, 9: 56-64. 10.1053/joca.2000.0350.PubMed

18.

Smith GN, Mickler EA, Albrecht ME, Myers SL, Brandt KD: Severity of medial meniscus damage in the canine knee after anterior cruciate ligament transection. Osteoarthritis Cartilage. 2002, 10: 321-326. 10.1053/joca.2002.0520.PubMed

19.

Berthiaume MJ, Raynauld JP, Martel-Pelletier J, Labonté F, Beau-doin G, Bloch DA, Choquette D, Haraoui B, Altman RD, Hochberg M, et al: Meniscal tear and extrusion are strongly associated with the progresion of knee osteoarthritis as assessed by quantitative magnetic resonance imaging. Ann Rheum Dis. 2005, 64: 556-563. 10.1136/ard.2004.023796.PubMedCentralPubMed

20.

Raynauld JP, Martel-Pelletier J, Berthiaume MJ, Beaudoin G, Choquette D, Haraoui B, Tannenbaum H, Meyer JM, Beary JF, Cline GA, et al: Long term evaluation of disease progression through the quantitative magnetic resonance imaging of symptomatic knee osteoarthritis patients: correlation with clinical symptoms and radiographic changes. Arthritis Res Ther. 2006, 8: R21-10.1186/ar1875.PubMedCentralPubMed

21.

Englund M, Roos EM, Lohmander LS: Impact of type of meniscal tear on radiographic and symptomatic knee osteoarthritis: a sixteen-year followup of meniscectomy with matched controls. Arthritis Rheum. 2003, 48: 2178-2187. 10.1002/art.11088.PubMed

22.

Englund M, Lohmander LS: Risk factors for symptomatic knee osteoarthritis fifteen to twenty-two years after meniscectomy. Arthritis Rheum. 2004, 50: 2811-2819. 10.1002/art.20489.PubMed

23.

Martel-Pelletier J, Lajeunesse D, Pelletier JP: Etiopathogenesis of osteoarthritis. Arthritis and Allied Conditions. A Textbook of Rheumatology. Edited by: Koopman WJ. 2005, Baltimore, MA: Lippincott, Williams & Wilkins, 2199-2226.

24.

Lajeunesse D, Massicotte F, Pelletier JP, Martel-Pelletier J: Subchondral bone sclerosis in osteoarthritis: Not just an innocent bystander. Modern Rheumatol. 2003, 13: 7-14. 10.1007/s101650300001.

25.

Felson DT, Chaisson CE, Hill CL, Totterman SM, Gale ME, Skinner KM, Kazis L, Gale DR: The association of bone marrow lesions with pain in knee osteoarthritis. Ann Intern Med. 2001, 134: 541-549.PubMed

26.

Felson DT, McLaughlin S, Goggins J, LaValley MP, Gale ME, Totterman S, Li W, Hill C, Gale D: Bone marrow edema and its relation to progression of knee osteoarthritis. Ann Intern Med. 2003, 139: 330-336.PubMed

27.

Bettica P, Cline G, Hart DJ, Meyer J, Spector TD: Evidence for increased bone resorption in patients with progressive knee osteoarthritis: longitudinal results from the Chingford study. Arthritis Rheum. 2002, 46: 3178-3184. 10.1002/art.10630.PubMed

28.

Hunter DJ, Hart D, Snieder H, Bettica P, Swaminathan R, Spector TD: Evidence of altered bone turnover, vitamin D and calcium regulation with knee osteoarthritis in female twins. Rheumatology (Oxford). 2003, 42: 1311-1316. 10.1093/rheumatology/keg373.

29.

Messent EA, Ward RJ, Tonkin CJ, Buckland-Wright C: Tibial cancellous bone changes in patients with knee osteoarthritis. A short-term longitudinal study using Fractal Signature Analysis. Osteoarthritis Cartilage. 2005, 13: 463-470. 10.1016/j.joca.2005.01.007.PubMed

30.

Brandt KD, Mazzuca SA, Katz BP, Lane KA, Buckwalter KA, Yocum DE, Wolfe F, Schnitzer TJ, Moreland LW, Manzi S, et al: Effects of doxycycline on progression of osteoarthritis: results of a randomized, placebo-controlled, double-blind trial. Arthritis Rheum. 2005, 52: 2015-2025. 10.1002/art.21122.PubMed

31.

Pelletier JP, Yaron M, Haraoui B, Cohen P, Nahir MA, Choquette D, Wigler I, Rosner IA, Beaulieu AD: Efficacy and safety of diac-erein in osteoarthritis of the knee: a double-blind, placebo-controlled trial. The Diacerein Study Group. Arthritis Rheum. 2000, 43: 2339-2348. 10.1002/1529-0131(200010)43:10<2339::AID-ANR23>3.0.CO;2-P.PubMed

32.

Dougados M, Nguyen M, Berdah L, Mazieres B, Vignon E, Lequesne M: Evaluation of the structure-modifying effects of diacerein in hip osteoarthritis: ECHODIAH, a three-year, placebo-controlled trial. Evaluation of the Chondromodulating Effect of Diacerein in OA of the Hip. Arthritis Rheum. 2001, 44: 2539-2547. 10.1002/1529-0131(200111)44:11<2539::AID-ART434>3.0.CO;2-T.PubMed

33.

Chevalier X, Giraudeau B, Conrozier T, Marliere J, Kiefer P, Goupille P: Safety study of intraarticular injection of interleukin 1 receptor antagonist in patients with painful knee osteoarthritis: a multicenter study. J Rheumatol. 2005, 32: 1317-1323.PubMed

34.

Chevalier X, Goupille P, Beaulieu AD, Burch FX, Conrozier T, Loeuille D, Kivitz AJ, Silver D, Kiefer P, Zhou L, et al: Results from a double blind, placebo-controlled, multicenter trial of a single intra-articular injection of anakinra (Kineret) in patients with osteoarthritis of the knee [Abstract]. Arthritis Rheum. 2005, 54: S507-

35.

Reginster JY, Deroisy R, Rovati LC, Lee RL, Lejeune E, Bruyere O, Giacovelli G, Henrotin Y, Dacre JE, Gossett C: Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet. 2001, 357: 251-256. 10.1016/S0140-6736(00)03610-2.PubMed

36.

Pavelka K, Gatterova J, Olejarova M, Machacek S, Giacovelli G, Rovati LC: Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med. 2002, 162: 2113-2123. 10.1001/archinte.162.18.2113.PubMed

37.

Bruyere O, Pavelka K, Rovati LC, Deroisy R, Olejarova M, Gat-terova J, Giacovelli G, Reginster JY: Glucosamine sulfate reduces osteoarthritis progression in postmenopausal women with knee osteoarthritis: evidence from two 3-year studies. Menopause. 2004, 11: 138-143. 10.1097/01.GME.0000087983.28957.5D.PubMed

38.

Michel BA, Stucki G, Frey D, De Vathaire F, Vignon E, Bruehlmann P, Uebelhart D: Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: a randomized, controlled trial. Arthritis Rheum. 2005, 52: 779-786. 10.1002/art.20867.PubMed

39.

Uebelhart D, Malaise M, Marcolongo R, DeVathaire F, Piperno M, Mailleux E, Fioravanti A, Matoso L, Vignon E: Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: a one-year, randomized, double-blind, multicenter study versus placebo. Osteoarthritis Cartilage. 2004, 12: 269-276. 10.1016/j.joca.2004.01.004.PubMed

40.

Clegg DO, Reda DJ, Harris CL, Klein MA, O'Dell JR, Hooper MM, Bradley JD, Bingham CO, Weisman MH, Jackson CG, et al: Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med. 2006, 354: 795-808. 10.1056/NEJMoa052771.PubMed

41.

Raynauld JP, Buckland-Wright C, Ward R, Choquette D, Haraoui B, Martel-Pelletier J, Uthman I, Khy V, Tremblay JL, Bertrand C, et al: Safety and efficacy of long-term intraarticular steroid injections in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2003, 48: 370-377. 10.1002/art.10777.PubMed

42.

Jubb RW, Piva S, Beinat L, Dacre J, Gishen P: A one-year, randomised, placebo (saline) controlled clinical trial of 500-730 kDa sodium hyaluronate (Hyalgan) on the radiological change in osteoarthritis of the knee. Int J Clin Pract. 2003, 57: 467-474.PubMed

43.

Carbone LD, Nevitt MC, Wildy K, Barrow KD, Harris F, Felson D, Peterfy C, Visser M, Harris TB, Wang BW, et al: The relationship of antiresorptive drug use to structural findings and symptoms of knee osteoarthritis. Arthritis Rheum. 2004, 50: 3516-3525. 10.1002/art.20627.PubMed

44.

Spector TD, Conaghan PG, Buckland-Wright JC, Garnero P, Cline GA, Beary JF, Valent DJ, Meyer JM: Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the BRISK randomized, controlled trial. Arthritis Res Ther. 2005, 7: R625-633. 10.1186/ar1716.PubMedCentralPubMed

45.

Schiff MH, DiVittorio G, Tesser J, Fleischmann R, Schechtman J, Hartman S, Liu T, Solinger AM: The safety of anakinra in high-risk patients with active rheumatoid arthritis: six-month observations of patients with comorbid conditions. Arthritis Rheum. 2004, 50: 1752-1760. 10.1002/art.20277.PubMed

46.

Dinarello CA: Biologic basis for interleukin-1 in disease. Blood. 1996, 87: 2095-2147.PubMed

47.

Greenfeder SA, Nunes P, Kwee L, Labow M, Chizzonite RA, Ju G: Molecular cloning and characterization of a second subunit of the interleukin 1 receptor complex. J Biol Chem. 1995, 270: 13757-13765. 10.1074/jbc.270.23.13757.PubMed

48.

Svenson M, Hansen MB, Heegaard P, Abell K, Bendtzen K: Specific binding of interleukin-1 (IL-1)-? and IL-1 receptor antagonist (IL-1ra) to human serum. High-affinity binding of IL-1ra to soluble IL-1 receptor type I. Cytokine. 1993, 5: 427-435. 10.1016/1043-4666(93)90032-Z.PubMed

49.

Casadio R, Frigimelica E, Bossu P, Neumann D, Martin MU, Tagliabue A, Boraschi D: Model of interaction of the IL-1 receptor accessory protein IL-1RAcP with the IL-1beta/IL-1R(I) complex. FEBS Lett. 2001, 499: 65-68. 10.1016/S0014-5793(01)02515-7.PubMed

50.

Liege S, Laye S, Li KS, Moze E, Neveu PJ: Interleukin 1 receptor accessory protein (IL-1RAcP) is necessary for centrally mediated neuroendocrine and immune responses to IL-1beta. J Neuroimmunol. 2000, 110: 134-139. 10.1016/S0165-5728(00)00331-3.PubMed

51.

Smeets RL, van de Loo FA, Joosten LA, Arntz OJ, Bennink MB, Loesberg WA, Dmitriev IP, Curiel DT, Martin MU, van den Berg WB: Effectiveness of the soluble form of the interleukin-1 receptor accessory protein as an inhibitor of interleukin-1 in collagen-induced arthritis. Arthritis Rheum. 2003, 48: 2949-2958. 10.1002/art.11234.PubMed

52.

Smith DE, Hanna R, Della Friend, Moore H, Chen H, Farese AM, MacVittie TJ, Virca GD, Sims JE: The soluble form of IL-1 receptor accessory protein enhances the ability of soluble type II IL-1 receptor to inhibit IL-1 action. Immunity. 2003, 18: 87-96. 10.1016/S1074-7613(02)00514-9.PubMed

53.

Economides AN, Carpenter LR, Rudge JS, Wong V, Koehler-Stec EM, Hartnett C, Pyles EA, Xu X, Daly TJ, Young MR, et al: Cytokine traps: multi-component, high-affinity blockers of cytokine action. Nat Med. 2003, 9: 47-52. 10.1038/nm811.PubMed

54.

Gabay C: IL-1 trap. Regeneron/Novartis. Curr Opin Investig Drugs. 2003, 4: 593-597.PubMed

55.

Saha N, Moldovan F, Tardif G, Pelletier JP, Cloutier JM, Martel-Pelletier J: Interleukin-1β-converting enzyme/Caspase-1 in human osteoarthritic tissues: Localization and role in the maturation of IL-1β and IL-18. Arthritis Rheum. 1999, 42: 1577-1587. 10.1002/1529-0131(199908)42:8<1577::AID-ANR3>3.0.CO;2-Z.PubMed

56.

Rudolphi K, Gerwin N, Verzijl N, van der Kraan P, van den Berg W: Pralnacasan, an inhibitor of interleukin-1beta converting enzyme, reduces joint damage in two murine models of osteoarthritis. Osteoarthritis Cartilage. 2003, 11: 738-746. 10.1016/S1063-4584(03)00153-5.PubMed

57.

Pelletier JP, Fernandes JC, Brunet J, Moldovan F, Schrier D, Flory C, Martel-Pelletier J: In vivo selective inhibition of mitogen-activated protein kinase kinase 1/2 in rabbit experimental osteoarthritis is associated with a reduction in the development of structural changes. Arthritis Rheum. 2003, 48: 1582-1593. 10.1002/art.11014.PubMed

58.

Bogoyevitch MA, Boehm I, Oakley A, Ketterman AJ, Barr RK: Targeting the JNK MAPK cascade for inhibition: basic science and therapeutic potential. Biochim Biophys Acta. 2004, 1697: 89-101.PubMed

59.

Vincenti MP, Brinckerhoff CE: The potential of signal transduction inhibitors for the treatment of arthritis: Is it all just JNK?. J Clin Invest. 2001, 108: 181-183. 10.1172/JCI200113508.PubMedCentralPubMed

60.

Han Z, Boyle DL, Chang L, Bennett B, Karin M, Yang L, Manning AM, Firestein GS: c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J Clin Invest. 2001, 108: 73-81. 10.1172/JCI200112466.PubMedCentralPubMed

61.

Ahmed S, Rahman A, Hasnain A, Goldberg VM, Haqqi TM: Phenyl N-tert-butylnitrone down-regulates interleukin-1 beta-stimulated matrix metalloproteinase-13 gene expression in human chondrocytes: suppression of c-Jun NH2-terminal kinase, p38-mitogen-activated protein kinase and activating protein-1. J Pharmacol Exp Ther. 2003, 305: 981-988. 10.1124/jpet.102.048611.PubMed

62.

Ridley SH, Sarsfield SJ, Lee JC, Bigg HF, Cawston TE, Taylor DJ, DeWitt DL, Saklatvala J: Actions of IL-1 are selectively controlled by p38 mitogen-activated protein kinase. Regulation of prostaglandin H synthase-2, metalloproteinases, and IL-6 at different levels. J Immunol. 1997, 158: 3165-3173.PubMed

63.

Badger AM, Bradbeer JN, Votta B, Lee JC, Adams JL, Griswold DE: Pharmacological profile of SB 20 a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. J Pharmacol Exp Ther. 3580, 279: 1453-1461.

64.

Pelletier JP, Jovanovic DV, Lascau-Coman V, Fernandes JC, Manning PT, Connor JR, Currie MG, Martel-Pelletier J: Selective inhibition of inducible nitric oxide synthase reduces progression of experimental osteoarthritis in vivo: possible link with the reduction in chondrocyte apoptosis and caspase 3 level. Arthritis Rheum. 2000, 43: 1290-1299. 10.1002/1529-0131(200006)43:6<1290::AID-ANR11>3.0.CO;2-R.PubMed

65.

Pelletier JP, Lascau-Coman V, Jovanovic D, Fernandes JC, Manning P, Currie MG, Martel-Pelletier J: Selective inhibition of inducible nitric oxide synthase in experimental osteoarthritis is associated with reduction in tissue levels of catabolic factors. J Rheumatol. 1999, 26: 2002-2014.PubMed

66.

Pelletier JP, Jovanovic D, Fernandes JC, Manning PT, Connor JR, Currie MG, Di Battista JA, Martel-Pelletier J: Reduced progression of experimental osteoarthritis in vivo by selective inhibition of inducible nitric oxide synthase. Arthritis Rheum. 1998, 41: 1275-1286. 10.1002/1529-0131(199807)41:7<1275::AID-ART19>3.0.CO;2-T.PubMed

67.

Laufer S, Tries S, Augustin J, Elsasser R, Albrecht W, Guserle R, Algate DR, Atterson PR, Munt PL: Acute and chronic anti-inflammatory properties of [2,2-dimethyl-6-(4-chlorophenyl)-7-phenyl-2,3-dihydro-1H-pyrrolizine-5-yl]-acetic acid. Arzneimittelforschung. 1995, 45: 27-32.PubMed

68.

Wallace JL, Carter L, McKnight W, Tries S, Laufer S: ML 3000 reduces gastric prostaglandin synthesis without causing mucosal injury. Eur J Pharmacol. 1994, 271: 525-531. 10.1016/0014-2999(94)90814-1.PubMed

69.

Laufer S, Tries S, Augustin J, Dannhardt G: Pharmacological profile of a new pyrrolizine derivative inhibiting the enzymes cyclo-oxygenase and 5-lipoxygenase. Arzneimittelforschung. 1994, 44: 629-636.PubMed

70.

Pelletier JP, Boileau C, Brunet J, Boily M, Lajeunesse D, Reboul P, Laufer S, Martel-Pelletier J: The inhibition of subchondral bone resorption in the early phase of experimental dog osteoarthritis by licofelone is associated with a reduction in the synthesis of MMP-13 and cathepsin K. Bone. 2004, 34: 527-538. 10.1016/j.bone.2003.11.021.PubMed

71.

Boileau C, Martel-Pelletier J, Jouzeau PY, Netter P, Moldovan F, Laufer S, Tries S, Pelletier JP: Licofelone (ML-3000), a dual inhibitor of both 5-lipoxygenase and cyclooxygenases, reduces the level of cartilage chondrocyte death in vivo in experimental dog osteoarthritis: inhibition of pro-apoptotic factors. J Rheumatol. 2002, 29: 1446-1453.PubMed

72.

Jovanovic DV, Fernandes JC, Martel-Pelletier J, Jolicoeur FC, Reboul P, Laufer S, Tries S, Pelletier JP: The in vivo dual inhibition of cyclooxygenase and lipoxygenase by ML-3000 reduces the progression of experimental osteoarthritis. Suppression of collagenase-1 and interleukin-1beta synthesis. Arthritis Rheum. 2001, 44: 2320-2330. 10.1002/1529-0131(200110)44:10<2320::AID-ART394>3.0.CO;2-P.PubMed

73.

Fahmi H, Di Battista JA, Pelletier JP, Mineau F, Ranger P, Martel-Pelletier J: Peroxisome proliferator-activated receptor gamma activators inhibit interleukin-1beta-induced nitric oxide and matrix metalloproteinase 13 production in human chondro-cytes. Arthritis Rheum. 2001, 44: 595-607. 10.1002/1529-0131(200103)44:3<595::AID-ANR108>3.0.CO;2-8.PubMed

74.

Fahmi H, Pelletier JP, Di Battista JA, Cheung HS, Fernandes J, Martel-Pelletier J: Peroxisome proliferator-activated receptor gamma acitvators inhibit MMP-1 production in human synovial fibroblasts by reducing the activity of the activator protein 1. Osteoarthritis Cartilage. 2002, 10: 100-108. 10.1053/joca.2001.0485.PubMed

75.

Cheng S, Afif H, Martel-Pelletier J, Pelletier JP, Li X, Farrajota K, Lavigne M, Fahmi H: Activation of peroxisome proliferator-activated receptor γ inhibits interleukin-1β-induced mPGES-1 expression in human synovial fibroblasts by interfering with Egr-1. J Biol Chem. 2004, 279: 22057-22065. 10.1074/jbc.M402828200.PubMed

76.

Boyault S, Simonin MA, Bianchi A, Compe E, Liagre B, Mainard D, Becuwe P, Dauca M, Netter P, Terlain B, et al: 15-Deoxy-delta12,14-PGJ2, but not troglitazone, modulates IL-1beta effects in human chondrocytes by inhibiting NF-kappaB and AP-1 activation pathways. FEBS Lett. 2001, 24-30. 10.1016/S0014-5793(01)02614-X.

77.

Bordji K, Grillasca JP, Gouze JN, Magdalou J, Schohn H, Keller JM, Bianchi A, Dauca M, Netter P, Terlain B: Evidence for the presence of peroxisome proliferator-activated receptor (PPAR) alpha and gamma and retinoid Z receptor in cartilage. PPARgamma activation modulates the effects of interleukin-1beta on rat chondrocytes. J Biol Chem. 2000, 275: 12243-12250. 10.1074/jbc.275.16.12243.PubMed

78.

Cuzzocrea S, Mazzon E, Dugo L, Patel NS, Serraino I, Di Paola R, Genovese T, Britti D, De Maio M, Caputi AP, et al: Reduction in the evolution of murine type II collagen-induced arthritis by treatment with rosiglitazone, a ligand of the peroxisome proliferator-activated receptor gamma. Arthritis Rheum. 2003, 48: 3544-3556. 10.1002/art.11351.PubMed

79.

Kobayashi T, Notoya K, Naito T, Unno S, Nakamura A, Martel-Pel-letier J, Pelletier JP: Pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, reduces the progression of experimental osteoarthritis in guinea pigs. Arthritis Rheum. 2005, 52: 479-487. 10.1002/art.20792.PubMed

80.

Renkiewicz R, Qiu L, Lesch C, Sun X, Devalaraja R, Cody T, Kald-jian E, Welgus H, Baragi V: Broad-spectrum matrix metalloproteinase inhibitor marimastat-induced musculoskeletal side effects in rats. Arthritis Rheum. 2003, 48: 1742-1749. 10.1002/art.11030.PubMed

81.

Wu J, Rush TS, Hotchandani R, Du X, Geck M, Collins E, Xu ZB, Skotnicki J, Levin JI, Lovering FE: Identification of potent and selective MMP-13 inhibitors. Bioorg Med Chem Lett. 2005, 15: 4105-4109. 10.1016/j.bmcl.2005.06.019.PubMed

82.

Engel CK, Pirard B, Schimanski S, Kirsch R, Habermann J, Klin-gler O, Schlotte V, Weithmann KU, Wendt KU: Structural basis for the highly selective inhibition of MMP-13. Chem Biol. 2005, 12: 181-189. 10.1016/j.chembiol.2004.11.014.PubMed

83.

Abbaszade I, Liu RQ, Yang F, Rosenfeld SA, Ross OH, Link JR, Ellis DM, Tortorella MD, Pratta MA, Hollis JM, et al: Cloning and characterization of ADAMTS11, an aggrecanase from the ADAMTS family. J Biol Chem. 1999, 274: 23443-23450. 10.1074/jbc.274.33.23443.PubMed

84.

Tortorella MD, Burn TC, Pratta MA, Abbaszade I, Hollis JM, Liu R, Rosenfeld SA, Copeland RA, Decicco CP, Wynn R, et al: Purification and cloning of aggrecanase-1: a member of the ADAMTS family of proteins. Science. 1999, 284: 1664-1666. 10.1126/science.284.5420.1664.PubMed

85.

Glasson SS, Askew R, Sheppard B, Carito B, Blanchet T, Ma HL, Flannery CR, Peluso D, Kanki K, Yang Z, et al: Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis. Nature. 2005, 434: 644-648. 10.1038/nature03369.PubMed

86.

Stanton H, Rogerson FM, East CJ, Golub SB, Lawlor KE, Meeker CT, Little CB, Last K, Farmer PJ, Campbell IK, et al: ADAMTS5 is the major aggrecanase in mouse cartilage in vivo and in vitro. Nature. 2005, 434: 648-652. 10.1038/nature03417.PubMed

87.

Cherney RJ, Mo R, Meyer DT, Wang L, Yao W, Wasserman ZR, Liu RQ, Covington MB, Tortorella MD, Arner EC, et al: Potent and selective aggrecanase inhibitors containing cyclic P1 substituents. Bioorg Med Chem Lett. 2003, 13: 1297-1300. 10.1016/S0960-894X(03)00124-0.PubMed

88.

Noe MC, Natarajan V, Snow SL, Wolf-Gouveia LA, Mitchell PG, Lopresti-Morrow L, Reeves LM, Yocum SA, Otterness I, Bliven MA, et al: Discovery of 3-OH-3-methylpipecolic hydroxamates: potent orally active inhibitors of aggrecanase and MMP-13. Bioorg Med Chem Lett. 2005, 15: 3385-3388. 10.1016/j.bmcl.2005.05.037.PubMed

89.

Manicourt DH, Altman RD, Williams JM, Devogelaer JP, Druetz-Van Egeren A, Lenz ME, Pietryla D, Thonar EJM: Treatment with calcitonin suppresses the responses of bone, cartilage, and synovium in the early stages of canine experimental osteoarthritis and significantly reduces the severity of the cartilage lesions. Arthritis Rheum. 1999, 42: 1159-1167. 10.1002/1529-0131(199906)42:6<1159::AID-ANR12>3.0.CO;2-Q.PubMed

90.

Myers SL, Brandt KD, Burr DB, O'Connor BL, Albrecht M: Effects of a bisphosphonate on bone histomorphometry and dynamics in the canine cruciate deficiency model of osteoarthritis. J Rheumatol. 1999, 26: 2645-2653.PubMed

91.

Howell DS, Altman RD, Pelletier J-P, Martel-Pelletier J, Dean DD: Disease modifying anti-rheumatic drugs current status of their application in animal models of osteoarthritis. Osteoarthritic Disorders. Edited by: Keuttner KE, Goldberg VM. 1999, Rosemont, IL: American Academy of Orthopaedic Surgeons, 365-378.

92.

Hayami T, Pickarski M, Wesolowski GA, McLane J, Bone A, Destefano J, Rodan GA, Duong le T: The role of subchondral bone remodeling in osteoarthritis: reduction of cartilage degeneration and prevention of osteophyte formation by alendronate in the rat anterior cruciate ligament transection model. Arthritis Rheum. 2004, 50: 1193-1206. 10.1002/art.20124.PubMed

93.

Pelletier JP, Boileau C, Boily M, Brunet J, Mineau F, Geng C, Reboul P, Laufer S, Lajeunesse D, Martel-Pelletier J: The protective effect of Licofelone on experimental osteoarthritis is correlated with the downregulation of the expression and the synthesis of several major cartilage catabolic factors: MMP-13, cathepsin K, and aggrecanases. Arthritis Res Ther. 2005, 7: R1091-R1102. 10.1186/ar1788.PubMedCentralPubMed

94.

McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, Peacock M, Miller PD, Lederman SN, Chesnut CH, et al: Denosumab in postmenopausal women with low bone mineral density. N Engl J Med. 2006, 354: 821-831. 10.1056/NEJMoa044459.PubMed

95.

Bateman J: Genetic aspects of osteoarthritis. Semin Arthritis Rheum. 2005, 34: 15-18. 10.1016/j.semarthrit.2004.03.006.PubMed

96.

Cho CH, Nuttall ME: Emerging techniques for the discovery and validation of therapeutic targets for skeletal diseases. Expert Opin Ther Targets. 2002, 6: 679-689. 10.1517/14728222.6.6.679.PubMed

97.

Bau B, Gebhard PM, Haag J, Knorr T, Bartnik E, Aigner T: Relative messenger RNA expression profiling of collagenases and aggrecanases in human articular chondrocytes in vivo and in vitro. Arthritis Rheum. 2002, 46: 2648-2657. 10.1002/art.10531.PubMed

98.

Aigner T, Bartnik E, Zien A, Zimmer R: Functional genomics of osteoarthritis. Pharmacogenomics. 2002, 3: 635-650. 10.1517/14622416.3.5.635.PubMed

99.

Aigner T, Zien A, Gehrsitz A, Gebhard PM, McKenna L: Anabolic and catabolic gene expression pattern analysis in normal versus osteoarthritic cartilage using complementary DNA-array technology. Arthritis Rheum. 2001, 44: 2777-2789. 10.1002/1529-0131(200112)44:12<2777::AID-ART465>3.0.CO;2-H.PubMed

100.

Attur MG, Dave M, Cipolletta C, Kang P, Goldring MB, Patel IR, Abramson SB, Amin AR: Reversal of autocrine and paracrine effects of interleukin 1 (IL-1) in human arthritis by type II IL-1 decoy receptor. Potential for pharmacological intervention. J Biol Chem. 2000, 275: 40307-40315. 10.1074/jbc.M002721200.PubMed

101.

Gelse K, Aigner T, Stöve J, Schneider H: Gene therapy approaches for cartilage injury and osteoarthritis. Curr Med Chem. 2005, 4: 265-279.

102.

Fernandes JC, Tardif G, Martel-Pelletier J, Lascau-Coman V, Dupuis M, Moldovan F, Sheppard M, Krishnan BR, Pelletier JP: In vivo transfer of interleukin-1 receptor antagonist gene in osteoarthritic rabbit knee joints: prevention of osteoarthritis progression. Am J Pathol. 1999, 154: 1159-1169.PubMedCentralPubMed

103.

Pelletier JP, Caron JP, Evans CH, Robbins PD, Georgescu HI, Jovanovic D, Fernandes JC, Martel-Pelletier J: In vivo suppression of early experimental osteoarthritis by IL-Ra using gene therapy. Arthritis Rheum. 1997, 40: 1012-1019.PubMed

104.

Attur MG, Dave MN, Leung MY, Cipolletta C, Meseck M, Woo SL, Amin AR: Functional genomic analysis of type II IL-1beta decoy receptor: potential for gene therapy in human arthritis and inflammation. J Immunol. 2002, 168: 2001-2010.PubMed

Title: Most recent developments in strategies to reduce the progression of structural changes in osteoarthritis: today and tomorrow
Authors: Jean-Pierre Pelletier
Johanne Martel-Pelletier
Jean-Pierre Raynauld
Publication date: 01-04-2006
Publisher: BioMed Central
Published in: Arthritis Research & Therapy / Issue 2/2006
Electronic ISSN: 1478-6362
DOI: https://doi.org/10.1186/ar1932

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2006

Variability in synovial inflammation in rheumatoid arthritis investigated by microarray technology

Proteoglycan 4 downregulation in a sheep meniscectomy model of early osteoarthritis

CXCL12 is displayed by rheumatoid endothelial cells through its basic amino-terminal motif on heparan sulfate proteoglycans

Suppression of inflammation by low-dose methotrexate is mediated by adenosine A2A receptor but not A3receptor activation in thioglycollate-induced peritonitis

Patients, their doctors, nonsteroidal anti-inflammatory drugs and the perception of risk

Methotrexate in rheumatoid arthritis is frequently effective, even if re-employed after a previous failure

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials